Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.7202
Nov 20 • 3:58 PM ET Dollar change-0.1008 Percentage change(-12.28%)
Aftermarket Close
0.7202
Aftermarket • 5:00 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
-
Market Cap
3.19M
Enterprise Value
-12.81M
Income
-12.76M
Sales
1.00M
Book/sh
3.46
Cash/sh
3.68
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13
IPO
Feb 13, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
3.19
P/B
0.21
P/C
0.20
P/FCF
-
EV/EBITDA
-
EV/Sales
-12.81
Quick Ratio
7.91
Current Ratio
7.91
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-2.93
EPS next Y
-0.73
EPS next Q
-0.14
EPS this Y
60.23%
EPS next Y
30.48%
EPS next 5Y
33.40%
EPS past 3/5Y
75.03% 65.58%
Sales past 3/5Y
- -
EPS Y/Y TTM
-18.90%
Sales Y/Y TTM
-100.00%
EPS Q/Q
-4582.26%
Sales Q/Q
-
Insider Own
11.64%
Insider Trans
0.00%
Inst Own
35.58%
Inst Trans
7.13%
ROA
-48.87%
ROE
-67.70%
ROIC
-82.76%
Gross Margin
84.19%
Oper. Margin
-890.17%
Profit Margin
-1276.30%
SMA20
-50.72%
SMA50
-65.83%
SMA200
-69.26%
Trades
Shs Outstand
4.42M
Shs Float
3.91M
52W High
2.91 -75.25%
52W Low
0.78 -7.67%
Volatility
16.29% 12.42%
ATR (14)
0.14
RSI (14)
13.74
Beta
0.07
Rel Volume
1.89
Avg Volume
34.15K
Volume
64,692
Perf Week
-41.45%
Perf Month
-68.96%
Perf Quarter
-73.81%
Perf Half Y
-71.87%
Perf YTD
-63.44%
Perf Year
-59.99%
Perf 3Y
-85.71%
Perf 5Y
-99.86%
Perf 10Y
-99.99%
Prev Close
0.82
Price
0.72
Change %
-12.28%
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
PresidentDr. Brian M. Strem Ph.D.
Chief Financial OfficerMs. Melissa Tosca CPA
Executive Vice President of CMC & OperationsDr. Stefan Sperl Ph.D.
Executive VP and Head of Clinical Development & Regulatory AffairsMr. Keith J. Lane M.B.A.